USPTO Patent Applications - Therapeutics (A61P)

Single-Chain Fragment Variable Targeting KRAS G12V CAR T-Cell Therapy

USPTO published patent application US20260108609A1 on April 23, 2026, filed May 31, 2024, for a single-chain fragment variable (scFv) targeting KRAS G12V and a chimeric antigen receptor (CAR). The invention modifies a T cell receptor to recognize KRAS G12V mutant polypeptides presented by HLA-A*02:01, retaining the extracellular signaling domain linked to a CD3ζ-derived intracellular signaling domain for potential tumor treatment applications including CAR-T and NK cell therapy.

Treatment of Autoimmune Diseases Having a Pathogenic T Cell State

The Brigham and Women's Hospital, Inc. filed patent application US20260108606A1 on October 23, 2025, covering methods of treating autoimmune and inflammatory diseases by targeting pathogenic immune cell states. Inventors Ana Carrizosa Anderson and Davide Mangani disclosed novel gene dependencies in pathogenic immune cells and methods for modifying immune cells characterized by that state. CPC classifications span A61K, A61P 37/06, C12N 15/85, and C12N 2800/107.

CD5 CAR Immune Cells for Cancer Treatment

The USPTO has published patent application US20260108608A1, filed October 4, 2023, for CD5-targeting chimeric antigen receptor (CAR) immune cells co-expressing OX40 ligand and IL-15. The application claims immune cells demonstrating synergistic tumor cell-killing activity with improved viability and in vitro proliferation rates as an anticancer cell therapy. Inventors include Seung Min Kim, Eunsol Lee, Hyun Seung Sun, Hansol Kim, Sunglim Cho, Miyoung Jung, and Bokyung Min. The claimed composition is directed to treating CD5-positive tumors including lymphocytic leukemia.

Immune Cell Conjugates and Methods for Producing and Using the Same

Sandigene Inc. has published US Patent Application US20260108621A1, filed October 16, 2025 under Application No. 19360236, covering surface-modified immune cells with covalently bound linkers and non-antibody ligands selective to target-cell receptors. The application names Yanwen Fu, Reyna Koreen V. Lim, Changyou Lin, and Moli Liu as inventors. The patent covers applications in anticancer therapeutics (CPC: A61P 35/00) and cell production methods (CPC: C12N 5/0006).

US20260108627A1 mRNA Lipid Nanoparticle Compositions for Hypercholesterolemia and Cardiovascular Disease Treatment

The USPTO published application US20260108627A1 on April 23, 2026, disclosing compositions and methods for treating hypercholesterolemia and/or cardiovascular disease using lipid nanoparticle delivery systems for mRNA-based therapeutics. The application names six inventors: Fuxin Shi, Wenhu Cao, Ye Chen, Huanle Liu, Han Qiu, and Leqi Liao, with a filing date of September 21, 2023. CPC classifications include A61K 48/005, A61P 3/06, C12N 9/226, and C12N 15/111, indicating lipid nanoparticle formulations and gene therapy approaches.

Cationic Lipid Compositions for Tissue-Specific Delivery

USPTO published patent application US20260108623A1 filed by Shikha Mishra and Xavier De Mollerat Du Jeu on December 10, 2025. The application covers cationic lipid compositions for delivering bioactive agents—therapeutic or diagnostic—specifically to spleen tissue, using lipid aggregates that do not require biomolecular targeting. The compositions include cationic lipids, helper lipids, and a biostability enhancing agent.

Bispecific CARs Targeting CD20 BCMA, AbelZeta, Autoimmune, Cancer

AbelZeta Inc. filed US Patent Application US20260108557A1 for a bispecific chimeric antigen receptor (CAR) targeting both CD20 and BCMA antigens simultaneously. The CAR construct comprises an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The application was filed on October 13, 2025, and published on April 23, 2026, with claims directed to methods of treating autoimmune disorders and cancer using the disclosed CAR.

Bifidobacterium Longum Subsp. Infantis BI03 Strain for Alleviating Parkinson's Disease

The USPTO has published application US20260108568A1 for a Bifidobacterium longum subsp. infantis BI03 strain (CGMCC No. 24473, deposited March 7, 2022) for alleviating Parkinson's disease. The application claims the strain can alleviate Parkinson's-related dyskinesia and corticosterone elevation, weaken associated neuroinflammation, promote glutathione, and reduce brain oxidative stress damage. Inventors include Shuguang FANG, Yao DONG, Yixuan FAN, Zhonghui GAI, and Jianguo ZHU; the application was filed May 27, 2024.

EGFR Inhibitors for Treatment-Resistant Non-Small Cell Lung Cancer

USPTO has published patent application US20260108524A1 for methods of treating treatment-resistant non-small cell lung cancer using EGFR inhibitors. The application, filed October 16, 2023, names David A. Nathanson, Jonathan Tsang, and Timothy F. Cloughesy as inventors. CPC classifications include A61K 31/519, A61K 31/517, and A61P 35/00. This publication represents new intellectual property activity in the targeted oncology space.

FGF21 GLP1 Double Gene-Modified Mesenchymal Stem Cell Patent Application for Metabolic Disease Treatment

The USPTO published patent application US20260108558A1, filed August 21, 2025, covering a modified mesenchymal stem cell engineered to co-express FGF21 and GLP-1 proteins, intended for treating metabolic diseases. The application names inventors Haifeng DUAN, Binghua XUE, Jing XIE, and Zhenli ZHANG, and specifies CPC classifications including A61K 35/28, A61P 3/10, C07K 14/50, C07K 14/605, and various C12N cellular-therapy classifications. Publication of this application creates prior art that may affect freedom-to-operate analyses for parties developing related cellular-therapy approaches for metabolic disease.

Methods of Treating Fibromyalgia With Psilocybin Compositions - Tryp Therapeutics

Tryp Therapeutics Inc. filed patent application US20260108545A1 with the USPTO on September 11, 2023 (application no. 19110772), published April 23, 2026. The application covers methods for treating fibromyalgia using psychedelics such as psilocybin or metabolites thereof, optionally combined with psychotherapy, with patient outcomes assessed through observer-rated and subject-reported measures as well as biological and clinical indicators. The inventors are James GILLIGAN and Peter GUZZO. Pharmaceutical and biotech companies pursuing psychedelic-based therapeutic research should monitor this filing as it may affect competitive patent positioning in fibromyalgia treatment.

US20260108572A1 - Alzheimer's Dementia Suppressant Using Sesamum Indicum Extract

USPTO published patent application US20260108572A1, filed September 1, 2023 and made publicly available on April 23, 2026, disclosing an Alzheimer-type dementia suppressant composition and method of manufacture using an aboveground part of Sesamum indicum (sesame plant) or an extract thereof as the active ingredient. The application names Sakamoto Yakusouen, LLC as assignee and Johji YAMAHARA as inventor. CPC classifications include A61K 36/185, A61K 31/7048, A61P 25/28, and related formulation codes A61K 2236/17, A61K 2236/333, A61K 2236/51, and A61K 2236/53. The application does not yet represent an issued patent and carries no compliance obligation.

Anti-Cancer Therapy Methods Using Autophagy Induction via DBI Inhibition

USPTO published patent application US20260108602A1 covering methods and systems for improving anti-cancer therapies through autophagy induction via inhibition of extracellular diazepam binding inhibitor (DBI). Inventors include Mark de Boer, Guido Kroemer, Léa Montegut, Isabelle Martins, Hui Pan, Hui Chen, and Sijing Li, with application number 19361314 filed October 17, 2025. The application claims therapeutic compositions, methods, and regimens for cancer treatment, including chemo- and immunotherapies.

Engineered Immune Effector Cell with CD16 Protein for Shear Resistance

USPTO published patent application US20260108605A1, filed September 27, 2023, covering a genetically modified immune effector cell expressing a recombinant human CD16 protein engineered with amino acid additions, deletions, and replacements that confer enhanced shear resistance. The application names five inventors: Fuwei JIANG, Tingting LIU, Yifang WANG, Cuiqing YANG, and Zhuoxiao CAO. CPC classifications span immunology (A61K 38/1774, A61K 39/39558), oncology (A61P 35/00), and protein engineering (C07K 14/7051, C07K 16/2803).

Probiotic Preparation Containing Akkermansia Muciniphila Akk11 Strain for Alleviating Hypertension

USPTO published patent application US20260108565A1 on April 23, 2026, covering a probiotic preparation combining Akkermansia muciniphila Akk11 strain with Lactobacillus rhamnosus LRa05 strain for alleviating hypertension. The application, originally filed July 9, 2024 under application number 18879015, names Shuguang Fang, Yao Dong, Yunjiao Zhao, Zhonghui Gai, and Jianguo Zhu as inventors. The CPC classifications include A61K 35/741, A61P 9/12, and A61K 2035/115, indicating pharmaceutical preparations containing probiotics and anti-hypertensive agents.

Mycobacteriophage Compositions and Related Methods, Oregon State University

USPTO published patent application US20260108571A1 for Oregon State University on April 23, 2026, covering isolated bacteriophages with lytic activity against mycobacterial species, including the specific phage Pill582 and variants thereof. The application (filed 2025-10-20, Application No. 19363116) discloses phage cocktails, pharmaceutical compositions, and methods for treating mycobacterial infections and associated disease conditions.

University of Chicago Bacteriophage Patent for Bacterial Infections

The University of Chicago has received a published patent application (US20260108570A1) for bacteriophage compositions and methods targeting Enterobacteriaceae infections, including Klebsiella. The application, filed August 1, 2023, covers isolated bacteriophage sequences with at least 99% identity to SEQ ID NO:1-74, along with associated devices, kits, and treatment methods. Inventors include Mark MIMEE and Ella ROTMAN.

Anti-IL6 Receptor Antibody Treats Rheumatoid Arthritis

USPTO published patent application US20260108601A1 on April 23, 2026, filed September 22, 2025, covering methods of treating rheumatoid arthritis using an anti-IL6 receptor antibody in subjects with specific serum biomarker concentrations. The application names Anita Boyapati, Jérôme Msihid, and Moshe E. Zilberstein as inventors. Pharmaceutical and biotechnology companies developing IL-6 targeted therapies for autoimmune conditions may wish to monitor this application's prosecution for potential freedom-to-operate considerations.

Compound Emulsion Injection for Nausea and Vomiting

The USPTO published patent application US20260097042A1 for a compound emulsion combining aprepitant and palonosetron hydrochloride for injection. The formulation claims improved stability and enhanced patient adherence in preventing and treating nausea and vomiting. The application was filed on May 30, 2025.

Compositions and Methods for IV Administration of ABDNAZ for Cancer Treatment

USPTO published patent application US20260097013A1 for compositions and methods for intravenous administration of ABDNAZ (2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone) for cancer treatment. The application, filed on 2025-06-11, covers formulations containing autologous whole blood and ABDNAZ for rapid IV infusion. Inventors: Bryan T. Oronsky, Jan Scicinski, and Scott Caroen.

Epoxytiglienone Compounds for Disrupting Gram-negative Bacterial Biofilms

The USPTO has published patent application US20260097011A1 for epoxytiglienone compounds designed to disrupt biofilms comprising Gram-negative bacteria. The application covers methods of dispersing established biofilms through localized administration, including topical or injection delivery, as well as methods for preventing biofilm formation on medical devices. Inventors include David William Thomas, Paul Warren Reddell, Glen Mathew Boyle, and others. The application was filed on December 2, 2025.

Compounds and Combinations Thereof for Treating Neurological and Psychiatric Conditions

The USPTO published patent application US20260097006A1 by inventor Herriot Tabuteau, filed September 4, 2025, covering compounds and combinations containing dextromethorphan for treating neurological and psychiatric conditions. The application discloses dosage forms and drug delivery systems typically combined with antidepressants such as bupropion. This publication makes the application publicly available for review and potential opposition.

CHIMERIC ANTIGEN RECEPTOR SPACERS

The USPTO published Lyell Immunopharma's patent application US20260098075A1 for chimeric antigen receptors (CARs) incorporating immunoglobulin-derived spacers, such as hinge or loop regions, designed to enhance cytokine release compared to CARs with non-Ig-derived spacers. The spacers may be derived from human immunoglobulins (IgAQ1, IgA2, IgD, IgE, IgG1-4, IgM) or non-human sources (e.g., mouse IgG2A), and may be configured as modular constructs combining multiple Ig hinges or fragments thereof. Filed September 8, 2025.

Rapid Conjugate Vaccine Manufacturing Method, Inventprise

Rapid Conjugate Vaccine Manufacturing Method, Inventprise

Oncolytic Vaccinia Viruses and Recombinant Viruses and Methods of Use Thereof

The USPTO published patent application US20260097116A1 by ViroMissile, Inc. covering clonal strains of vaccinia virus engineered as oncolytic virus therapies for treating cancer. The application includes claims for recombinant vaccinia viruses with inactivating mutations and heterologous gene products, pharmaceutical compositions, and methods of use for anti-tumor therapy.

CD19/CD22 CAR T Cell Treatment for High-Risk Pediatric Acute Lymphoblastic Leukemia

The USPTO published patent application US20260097122A1 for CD19/CD22 chimeric antigen receptor (CAR) T-cell products and methods for treating high-risk or relapsed CD19+ or CD22+ haematological malignancies, specifically pediatric acute lymphoblastic leukemia. The application was filed on May 10, 2023, under application number 18862269. Inventors include Martin Pulé, Persis Amrolia, and Sara Ghorashian.

GIP/GLP-1 Dual Agonist Formulations for Metabolic and Liver Disorders

The USPTO published patent application US20260097126A1 disclosing pharmaceutical formulations of small molecule GIP/GLP-1 dual receptor agonists for treating metabolic and liver disorders. The application (No. 18995773) was filed on July 18, 2023, by inventors Brian Lian, Geoffrey E. Barker, Maureen Barnes, Brahmachary Enugurthi, and Jake Gonzalez. The formulations include compounds classified under CPC codes A61K 47/548, A61K 9/0019, and others, with therapeutic applications targeting A61P 3/06 (metabolic disorders).

Epigenetic Editing Tool for Targeting Hepatitis B Virus Gene

USPTO published patent application US20260097133A1 for an epigenetic editing tool targeting hepatitis B virus genes, filed by inventors Wenbo Peng, Junzheng Zhao, Shaoshuai Mao, Leilei Wu, Di Sun, Ruimin Lv, Ying Zang, and Junjian Liu on December 4, 2025. The application covers compositions and methods for epigenetic modification of HBV genes for therapeutic use in biomedicine.

Fluorescent Probe Compounds for Tumor-Targeted Imaging and Synthesis Methods

USPTO published patent application US20260097137A1 by Hebei Medical University for fluorescent probe compounds utilizing a pyrrolo[2,3-d]pyrimidine core structure conjugated to a fluorescent dye for tumor-targeted imaging. The probes demonstrate high affinity and selectivity for tumor cells, rapid clearance from normal tissues, and prolonged retention at tumor sites. The invention enables in vitro and in vivo tracking, receptor affinity studies, and intraoperative navigation applications.

Enterin Patents Novel Aminosterol ENT-03 Compounds and Compositions

The USPTO published patent application US20260098052A1 for Enterin, Inc., covering novel aminosterol ENT-03 compounds, compositions comprising the same, and methods of making and using the same. The inventors are Denise Barbut and Michael Zasloff. The application was filed December 10, 2025, under application number 19415736. The CPC classifications indicate therapeutic applications including nervous system conditions (A61P 25/00).

SNIPR Biome ApS - Treating and Preventing Microbial Infections

USPTO published patent application US20260098259A1 assigned to SNIPR Biome ApS, covering methods for treating microbial infections including acute conditions such as sepsis, septicemia, SIRS, and septic shock. The application also discloses methods for controlling microbiologically influenced corrosion (MIC) and biofouling in industrial or domestic systems.

Ether Lipids Hyperactivate Dendritic Cells - Corner Therapeutics

The USPTO published patent application US20260097111A1 by Corner Therapeutics, Inc. on April 9, 2026, covering ether lipid (ETL) and ether phospholipid (ETPL) compounds for hyperactivating mammalian dendritic cells, including compositions combined with pathogen recognition receptor agonists, antigens, and dendritic cells. The application was originally filed on October 18, 2023.

Liposomal Compositions With Anti-Cancer Agents, Tumor-Targeting Lipopeptides

The USPTO published patent application US20260096988A1 on April 9, 2026, filed by inventors Debabrata Mukhopadhyay, Vijay S. Madamsetty, and Krishnendu Pal. The application covers liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides, as well as nanodiamond complexes and particles as carriers for anti-cancer agents. This publication provides public notice of the intellectual property claims related to advanced drug delivery compositions for cancer treatment. The pharmaceutical and biotechnology industries should monitor this application for potential impacts on cancer therapeutics development.

Silicon Nanoparticle Delivery System for Controlled Release of Nucleic Acids Including siRNA and mRNA

The USPTO published patent application US20260096997A1 assigned to SISAF LIMITED, filed November 6, 2025. The application covers a composition for controlled release of nucleic acids such as short interfering RNA (siRNA) or messenger RNA (mRNA), comprising silicon nanoparticles comprising at least 50% by weight silicon, at least one amino acid, and at least one lipid. The CPC classifications indicate primary focus on pharmaceutical preparations (A61K) and therapeutic uses including ophthalmological applications (A61P 27/02).

Modified oHSV with HRG for Cancer Therapy

The USPTO published patent application US20260097088A1 for a modified oncolytic herpes simplex virus (oHSV) engineered with an expression cassette encoding histidine-rich glycoprotein (HRG) for use in cancer therapy. The invention, filed on August 17, 2023 (Application No. 19113359), leverages virotherapy to selectively target and lyse cancer cells while sparing normal cells. The inventors are Chun-Yu Chen, Pin-Yi Wang, and Timothy P. Cripe.

Parsnip Extract Composition for Intestinal Health and Leaky Gut Treatment

USPTO published patent application US20260097089A1 for a composition containing parsnip extract as an active ingredient. The composition is designed to reduce tight junction protein downregulation, promote beneficial intestinal bacteria proliferation, maintain acidic intestinal environment, and reduce intestinal permeability. The application indicates the composition may be used in foods, feeds, pharmaceuticals, or quasi-drugs for improving intestinal health and preventing or treating leaky gut syndrome, obesity, or metabolic diseases.

Herbal Medicine Extracts RM01 for Alzheimer's Treatment

The USPTO has published patent application US20260097090A1, filed September 26, 2023, and published April 9, 2026, covering herbal extract compositions for treating neurodegenerative diseases including Alzheimer's disease. The composition includes extracts from Ophiopogon japonicus, Barbary Wolfberry, Rhizoma Acori tatarinowii, and Codonopsis pilosula. This is a patent application publication, not a granted patent, and does not confer any regulatory approval for the claimed treatments.

Cancer Treatment Using Thyroid Hormone Analogs T2 and RT3

USPTO published patent application US20260097100A1 filed by Keith Roger Latham and Regina L. Garland on September 25, 2025, covering methods and compositions for treating cancer through induction of tumor cell differentiation using thyroid hormone analogs such as T2 and RT3. The application discloses pharmaceutical compositions including topical formulations for skin cancer and delivery systems for systemic administration.

Peptide Analogue for Treatment of Diabetes or Obesity

USPTO published patent application US20260097101A1 for a peptide analogue of pancreatic polypeptide (PP) intended for treating diabetes or obesity. Filed September 6, 2023 under application number 19110570, the invention also covers methods of treatment and use in manufacturing a medicament for these conditions.

Methods for Treating Fatty Liver Disease (NASH) with Resmetirom

USPTO published patent application US20260097039A1 disclosing methods of treating fatty liver disease (non-alcoholic steatohepatitis/NASH) and improving liver fibrosis using resmetirom (2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile) or its pharmaceutical salts. Inventors: Rebecca Taub and Dominic Labriola. Application filed December 10, 2025, and published April 9, 2026. This is a publication of a patent application, not a granted patent.

Reboxetine Patent Application for Narcolepsy and Cataplexy Treatment

USPTO published patent application US20260097040A1 by Herriot Tabuteau covering methods of treating narcolepsy with cataplexy using reboxetine or esreboxetine. The application includes pharmaceutical compositions and instructions for use in treating the condition. Filing date was December 11, 2025, with publication on April 9, 2026.

Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells

USPTO published patent application US20260097131A1 titled 'Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells.' The application (filed December 11, 2025) discloses compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo using non-viral delivery of polynucleotides encoding transcription factors. The patent application is now publicly available.

ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF

The USPTO published patent application US20260098078A1 covering activin receptor type II chimera polypeptides for treating conditions involving muscle weakness and atrophy, bone damage, blood disorders such as anemia, thrombocytopenia, and neutropenia, as well as fibrosis, metabolic disorders, and pulmonary hypertension. The application describes extracellular ActRII chimeras optionally fused to Fc domains as therapeutic agents.

Ypsomed AG Injection Device with Improved Conveying Element Patent Application

The European Patent Office published patent application EP4159257A1 for an injection device with improved conveying element, filed by Ypsomed AG. The application lists six inventors and covers IPC classifications A61M 5/20, A61M 5/24, and A61M 5/315 relating to injection mechanisms. The application is designated for validation in 28 European member states including Germany, France, the United Kingdom, Italy, and Spain.

Atovaquone Patent, Mast Cell Inflammatory Disease Treatment

Atovaquone Patent, Mast Cell Inflammatory Disease Treatment

mRNA, Protein Vaccine Compositions for Influenza

The USPTO published patent application US20260097112A1 by inventors Jacob Glanville et al. covering vaccine compositions comprising combinations of influenza antigens. The application discloses mRNA/LNP, recombinant protein, virus-like particle (VLP), and DNA vaccine formulations. Filing date was October 17, 2025.

Modified-Release Minoxidil Compositions and Methods for Hair Loss Treatment

The USPTO published patent application US20260097035A1 filed by inventor Reid Waldman on December 10, 2025, covering modified-release minoxidil compositions for treating hair loss. The application discloses pharmaceutical formulations for oral administration of modified-release minoxidil and methods of using the compositions for hair loss treatment.

Neuroplasticity Treatment Method with Neurostimulation and Dopamine Agonist for Depression

USPTO published patent application US20260097224A1 disclosing a method for treating neuroplasticity-related conditions by administering a dopamine receptor agonist combined with neuroplasticity-modulating drugs prior to or simultaneously with targeted energy-based neurostimulation, repeated within one day. The preferred embodiment targets depression using transcranial magnetic stimulation. Inventors are Donald A. Vaughn and Jonathan A.S. Downar, with application number 19274159 filed July 18, 2025.

Plant-Based DHA and Berberine Compositions for Treating Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease

The USPTO published patent application US20260097024A1, filed October 7, 2025, covering compositions and methods for treating obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease using synergistically effective amounts of plant-based DHA and berberine. Inventors are Roger Catarino and William Kuhne. The application has been made publicly available as part of the 18-month patent publication process.

Proton Pump Inhibitors for Inhibition of Aortic Valve Calcification

USPTO published patent application US20260097026A1 for the use of proton pump inhibitors including prazole compounds to inhibit calcification of aortic valves, treating aortic sclerosis and stenosis. The application was filed on October 3, 2023, with inventors Arsenii Zabirnyk, Ingvar Jarle Vaage, and Kåre-Olav Stensløkken. The invention is classified under CPC codes A61K 31/4439 and A61P 9/10.